RxDoctor Payments Data

Brandi Fleenor, MD

Neurology · Savannah, GANPI 1730475740

Payments from drug & device makers

$46,872in general payments, 2019–2025

Across 768 payments — averaging $61.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$36K
  • UCB, Inc.$962
  • TG Therapeutics, Inc.$870
  • EMD Serono, Inc.$574
  • Novartis$526
  • Biogen$486
  • plus $7K from 52 others

What the payments were for

  • Speaking & faculty fees$32,52569%
  • Travel & lodging$8522%
  • Food & beverage$13,21328%
  • Education$2831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)255$36,305
UCB, Inc.49$962
TG Therapeutics, Inc.19$870
EMD Serono, Inc.37$574
Novartis36$526
Biogen22$486
Lundbeck LLC23$467
Sunovion Pharmaceuticals Inc.48$464
Argenx US, Inc.19$462
AstraZeneca(2 entities)10$424
Pfizer25$411
Amgen(2 entities)18$389
Teva Pharmaceuticals USA, Inc.19$359
Sanofi8$298
Lilly USA, LLC16$292
SK Life Science, Inc.10$257
Takeda Pharmaceuticals U.S.A., Inc.12$234
MDD US Operations, LLC7$221
Neurocrine Biosciences, Inc.8$217
Neurelis, Inc.10$212
Eisai Inc.8$177
Mallinckrodt Hospital Products Inc.8$167
Jazz Pharmaceuticals Inc.9$159
Johnson & Johnson(2 entities)4$158
Ipsen Biopharmaceuticals, Inc7$126
Harmony Biosciences LLC6$125
Averitas Pharma Inc.5$123
Catalyst Pharmaceuticals, Inc.6$116
Acadia Pharmaceuticals Inc7$111
Livanova USA, Inc.1$108
Axsome Therapeutics, Inc.5$99
Otsuka America Pharmaceutical, Inc.4$71
Merz Pharmaceuticals, LLC3$67
Greenwich Biosciences, Inc.4$67
CSL Behring1$66
Scilex Pharmaceuticals Inc.3$63
Alnylam Pharmaceuticals Inc.3$59
Banner Life Sciences, LLC3$57
Adamas Pharmaceuticals, Inc.3$47
Supernus Pharmaceuticals, Inc.3$46
Impel Pharmaceuticals LLC2$41
Immedica Pharma US, Inc.2$40
Vanda Pharmaceuticals Inc.2$37
Genentech USA, Inc.2$36
Amneal Pharmaceuticals LLC2$31
Biohaven Pharmaceuticals, Inc.2$28
Xeris Pharmaceuticals, Inc.1$25
Tanabe Pharma America, Inc.1$23
Sumitomo Pharma America, Inc.1$21
E.r. Squibb & Sons, L.L.C.1$19
GE HealthCare1$18
Kyowa Kirin, Inc.1$17
Kedrion Biopharma, Inc.1$16
Upsher-smith Laboratories LLC1$16
Biohaven Pharmaceutical Holding Company Ltd.1$15
Aprecia Pharmaceuticals, LLC1$15
Saol Therapeutics Inc.1$15
ANI Pharmaceuticals, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,872 in reported general payments places this provider in the 85th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$302,871
Medicare patients
412
Services billed
16,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5015$533,815
NuplazidPimavanserin Tartrate31$155,302
Nurtec OdtRimegepant Sulfate44$68,098
AustedoDeutetrabenazine12$62,782
UbrelvyUbrogepant43$52,167
Aimovig AutoinjectorErenumab-Aooe18$20,870
RytaryCarbidopa/Levodopa17$20,483
Emgality PenGalcanezumab-Gnlm16$11,309
FingolimodFingolimod Hcl11$5,784
Dimethyl Fumarate34$5,562
Gabapentin328$4,055
Carbidopa-LevodopaCarbidopa/Levodopa232$4,029
Memantine Hcl270$3,984
Levetiracetam108$3,021
Pyridostigmine Bromide46$2,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$234$533,81515 claims
Acadia Pharmaceuticals IncNuplazid$111$155,30231 claims
PfizerNurtec Odt$411$68,09844 claims
Teva Pharmaceuticals USA, Inc.Austedo$359$62,78212 claims
AbbVieUbrelvy$36,305$52,16743 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$31$23,15963 claims
Lilly USA, LLCOlanzapine$292$56622 claims
Upsher-smith Laboratories LLCTopiramate$16$35673 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 506 neurology providers in Georgia.

Other neurology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →